Decision Diagnostics Corp. (DECN)
| Market Cap | 380.00 |
| Revenue (ttm) | 2.13M -3.1% |
| Net Income | -8.29M |
| EPS | -0.02 |
| Shares Out | 380.49M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12,800 |
| Open | 0.000001 |
| Previous Close | 0.000001 |
| Day's Range | 0.000001 - 0.000001 |
| 52-Week Range | 0.000001 - 0.0002 |
| Beta | 115.06 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About Decision Diagnostics
Decision Diagnostics Corp. develops smart phone based electronic medical record (EMR) technologies. The company offers prescription and non-prescription diagnostics; home testing products for the chronically ill; fulfillment services to direct to patient diabetes programs; and cell phone centric e-health products and technologies development services. It manufactures and distributes GenUltimate! glucose test strips, a Class II medical device for at-home use for the measurement of glucose; PetSure! glucose test strip for the glucose testing of d... [Read more]
News
Decision Diagnostics Update
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $300,000 In Decision Diagnostics Corp. To Contact Him Directly To Discuss Their OptionsNew York, Ne...
CEO charged in alleged COVID-19 fraud scheme
The Justice Department said late Friday that a federal grand jury has indicted a California chief executive for allegedly concocting a scheme to defraud investors with false claims about a COVID-19 te...